

HETEROCYCLES, Vol. 91, No. 3, 2015, pp. 515 - 525. © 2015 The Japan Institute of Heterocyclic Chemistry
Received, 12th December, 2014, Accepted, 26th January, 2015, Published online, 30th January, 2015
DOI: 10.3987/COM-14-13152

DEVELOPMENT OF A PROBE CONTAINING NOVEL FLUORESCENT TRICYCLIC-NUCLEOSIDE ANALOGS FOR DETECTING SINGLE NUCLEOTIDE POLYMORPHISMS

Ayako Moriya,^a Tokimitsu Ohki,^b Aya Hayai,^a and Yoshihito Ueno^{a,c,*}

^aFaculty of Applied Biological Sciences, Gifu University, ^bFaculty of Engineering, Gifu University, and ^cUnited Graduate School of Agricultural Science, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan; E-mail: uenoy@gifu-u.ac.jp

Abstract – Here we report the synthesis of nucleoside analogs containing several aryl groups at the 6-position of the fluorescent tricyclic base, 8-amino-3-(2,3-dihydroxypropyl)imidazo[4',5':5,6]pyrido[2,3-*d*]pyrimidine (**1**), to expand the fluorescence color range of single nucleotide polymorphism (SNP)-detecting probes. The identity of the RNA target bases could be determined using probes containing an analog with a phenyl group at the 6-position of **1**.

INTRODUCTION

Single nucleotide polymorphisms (SNPs) serve as markers for the prediction of an individual's response to certain drugs, and his or her risk of developing particular diseases. Therefore, the development of accurate, rapid, and cost-effective methods for SNP genotyping has become one of the most important subjects in pharmacogenomics, and for the advancement of personalized medicine.^{1,2}

Recently, we reported the synthesis of novel probes for SNP detection using the fluorescent nucleoside analogs **1** and **2** (Figure 1).^{3,4} The fluorescence intensity of **1** and **2** are dependent on solvent polarity; the nucleoside analogs **1** and **2** exhibit higher fluorescence in more polar solvents, such as methanol and water, than in less polar solvents, such as chloroform. The probes for detection of SNPs are comprised of **1** or **2** and a discriminating **D** nucleoside (dA, dG, dC, or dT) (Figure 2). When the **D**s are complementary to the target sequence, they can form base pairs with the target nucleosides, causing **1** or **2** to flip outside of the DNA helix, detectable by an increase in fluorescence intensity. However, when the target nucleoside is mismatched with the **D**, **1** or **2** intercalates into the DNA helix, since the tricyclic base-linked nucleoside analogs **1** and **2** are more intercalative than natural nucleosides. This weakens

their fluorescence intensity. Thus, the identity of the target nucleoside can be determined by comparing the fluorescence intensity of each duplex.

In this paper, we report on the synthesis of nucleoside analogs **3–6**, containing several aryl groups at the 6-position of the tricyclic base of **1**, to expand the fluorescence color range of the probes. In addition, we characterized the properties of DNA sequences containing analog **3** as SNP-detecting probes.




Figure 1. Structures of tricyclic base-linked nucleoside analogs





Figure 2. Principle of our SNP-detecting method using the fluorescent tricyclic nucleoside analog

RESULTS AND DISCUSSION

The method for synthesis of the tricyclic base-linked nucleoside surrogates **3–6** is shown in Scheme 1. Honjo et al. reported that treatment of 5-amino-4-cyano-1-(β -D-ribofuranosyl)imidazole with alkyl- and aryl-nitriles produced moderate yields of the corresponding 2-substituted adenine-arabinosides.⁵ Thus, we applied this method for synthesis of our compounds. Compound **7**, which was synthesized using a previously reported method,³ was treated with benzonitrile in a methanolic ammonia solution in a sealed steel tube at 110 °C, to give the corresponding 6-phenyl tricyclic derivative **8** in 80% yield. Deprotection of the isopropylidene group with 80% AcOH afforded **3** in 67% yield. Similarly, compounds **4–6** were obtained by treating **7** with 4-dimethylaminobenzonitrile, anisonitrile, or 2-furonitrile, followed with 80% AcOH in 64, 64, and 70% yields, respectively.



Scheme 1

The photophysical properties of compounds **3–6** were examined. Typical emission spectra for compounds **4–6** are shown in Figure 3. The fluorescence intensities of all compounds were dependent on solvent polarity. The fluorescence intensities of **3** and **6** were greater in more polar solvents, such as methanol and water, than in less polar solvents, such as chloroform. In contrast, the fluorescence intensity of the dimethylaminophenyl derivative **4** was greater in less polar solvents than in more polar solvents. The fluorescence intensity of **5** was lower in water than in other solvents. The fluorescence quantum yield (Φ) of **4** in chloroform was 0.51, whereas those of **3**, **5**, and **6** in methanol were 0.58, 0.61, and 0.31, respectively. Compound **4** showed an emission maximum at ~515 nm under 404-nm excitation in

chloroform, whereas **3**, **5**, and **6** exhibited emission maxima at ~410, ~417, and ~411 nm under 270-, 355-, and 282-nm excitation in methanol, respectively. Thus, the fluorescence emission maxima of **3**, **5**, and **6** were similar to those of **1** and **2**. Although the emission wavelength of **4** was longer than those of **1** and **2**, **4** was shown to be unsuitable as a nucleoside surrogate for use in this method because its fluorescence intensity was lower in more polar solvents than in less polar solvents.





Figure 3. Fluorescence emission spectra of analogs **3-6** in various solvents



Scheme 2

Next, to investigate the effect of an aryl group at the 6-position of the tricyclic base on SNP detection, we examined the properties of DNA probes containing **3** (**B**). The synthetic route for the phosphoramidite unit **14** is shown in Scheme 2. The amino group of **3** was protected with a (di-*n*-butylamino)methylene group in 82% yield. Then, the primary hydroxy group of **12** was protected with a 4,4'-dimethoxytrityl (DMTr) group in 71% yield. Phosphitylation of the hydroxy group of **13** gave the corresponding phosphoramidite unit **14** in 91% yield. In the present study, we chose a *CYP2C9* sequence containing an A1075(C) mutation as a model sequence.⁶ The sequences of the DNAs containing **3** and the target RNAs are given in Table 1. The 5'-P-probes, termed **BA**, **BG**, **BC**, and **BT**, contained **B** at the 5' end of the **Ds**, whereas the 3'-P-probes, termed **AB**, **GB**, **CB**, and **TB**, contained **B** at the 3' end of the **Ds**. All ODNs containing **3** (**B**) were synthesized using a DNA/RNA synthesizer.

Table 1. Oligonucleotide sequences. The underlined letters indicate discriminating bases. The italic letters represent target bases.

Abbreviation	Sequence
BA	5'-d(GAA GGT CAA <u>B</u> AG TAT CTC T)-3'
BG	5'-d(GAA GGT CAA <u>B</u> GG TAT CTC T)-3'
BC	5'-d(GAA GGT CAA <u>B</u> CG TAT CTC T)-3'
BT	5'-d(GAA GGT CAA <u>B</u> TG TAT CTC T)-3'
AB	5'-d(GAA GGT CAA <u>A</u> BG TAT CTC T)-3'
GB	5'-d(GAA GGT CAA <u>G</u> BG TAT CTC T)-3'
CB	5'-d(GAA GGT CAA <u>C</u> BG TAT CTC T)-3'
TB	5'-d(GAA GGT CAA <u>T</u> BG TAT CTC T)-3'
SrA	3'-r(CUU CCA GUU ACA UAG AGA)-5'
SrG	3'-r(CUU CCA GUU <i>G</i> CA UAG AGA)-5'
SrC	3'-r(CUU CCA GUU CCA UAG AGA)-5'
SrU	3'-r(CUU CCA GUU <i>U</i> CA UAG AGA)-5'

The fluorescence emission spectra of the duplexes containing the 3'-B-probes, **AB**, **GB**, **CB**, and **TB**, are shown in Figure 4 (left column). In all sequences, the fluorescence intensities were greatest when the discriminating bases were complementary to the target bases: the **AB** probe for the SrU target, the **CB** probe for the SrG target, the **TB** probe for the SrA target, and the **GB** probe for the SrC target. Thus, the identity of the target base can be determined using the 3'-B-probes. The results for probes containing the surrogate **B** at the 5' side of the discriminating bases (5'-B-probes) are also shown in Figure 4 (right column). The **BC** and **BG** probes were effective, but the **BT** and **BA** probes were ineffective as SNP-detecting probes. Using our method, when mismatched bases are present opposite the discriminating

bases, the nucleoside surrogate must be intercalated into the DNA-RNA duplex to quench the fluorescence of the surrogate. However, in the case of the **BT** and **BA** probes, the bulky phenyl group attached at the 6-position of the base moiety might prevent intercalation of the nucleoside surrogate **B** into the DNA-RNA duplex.




Figure 4. Fluorescence emission spectra of the duplexes

In conclusion, we demonstrated the synthesis of nucleoside surrogates **3 (B)**–**6** with aryl groups at the 6-position of the tricyclic base of **1** and DNA probes containing **3 (B)**. The fluorescence emission maxima of **3 (B)**, **5**, and **6** were similar to those of **1** and **2**, whereas the emission wavelength of **4** was longer than those of **1** and **2**. The 3'-B-probes were effective as SNP-detecting probes, but some of the 5'-B-probes were ineffective as SNP-detecting probes. The bulky phenyl group attached at the 6-position of some of the 5'-B-probes might prevent the nucleoside surrogate **B** from intercalating into the DNA-RNA duplex.

EXPERIMENTAL

General remarks. Thin-layer chromatography was carried out on Merck coated plates 60F₂₅₄. Silica gel column chromatography was carried out on Silica Gel 60N (spherical, neutral). ¹H-, ¹³C-, and ³¹P-NMR spectra were obtained with a JEOL ECX-400P or JEOL ECA-600 spectrometer. CDCl₃ (CIL) or DMSO-*d*₆ (CIL) was used as a solvent for obtaining NMR spectra. Chemical shifts (δ) are given in parts per million (ppm) downfield from (Me)₄Si (δ 0.00 for ¹H-NMR in CDCl₃), 80% H₃PO₄ (δ 0.00 for ³¹P-NMR), or a solvent (for ¹³C-NMR and ¹H-NMR in DMSO-*d*₆) as an internal reference with coupling constants (*J*) in Hz. The abbreviations s, d, and q signify singlet, doublet, and quartet, respectively.

(S)-8-Amino-3-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-6-phenylimidazo[4',5':5,6]pyrido[2,3-*d*]pyrimidine (8**).** Compound **7** (0.50 g, 1.83 mmol) and benzonitrile (3.8 g, 36.6 mmol) were dissolved in 7 M methanolic NH₃ (20 mL) in a stainless steel portable reactor at 0 °C. The portable reactor was sealed and the resulting solution was stirred at 140 °C for 2 days. After cooling the mixture, the tube was opened and the excess NH₃ was allowed to escape slowly. The mixture was concentrated. The residue was purified by column chromatography (SiO₂, 3% MeOH in CHCl₃) to give **8** (0.55 g, 1.47 mmol) in 80% yield: ¹H NMR (400 MHz, DMSO-*d*₆) δ 1.23 (s, 3H), 1.30 (s, 3H), 3.84 (dd, *J* = 8.7 and 5.5, 1H), 4.09 (dd, *J* = 8.3 and 6.8, 1H), 4.39-4.44 (dd, *J* = 14.2 and 6.4, 1H), 4.50-4.55 (dd, *J* = 14.2 and 4.1, 1H), 4.57-4.61 (m, 1H), 7.46-7.53 (m, 3H), 8.06 (s, 2H), 8.50 (dd, *J* = 6.7 and 4.6, 2H), 8.62 (s, 1H), 9.05 (s, 1H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 25.6, 27.1, 46.0, 66.7, 73.9, 105.4, 109.5, 123.8, 128.6, 128.8, 130.8, 134.2, 139.0, 150.7, 152.4, 156.7, 162.3, 164.6; HRMS (DART) calcd for C₂₀H₂₀N₆O₂ (M+H⁺): 377.1726, found; 377.1701. Anal. Calcd for C₂₀H₂₀N₆O₂·1/5H₂O: C, 63.21; H, 5.41; N, 22.11. Found: C, 63.26; H, 5.23; N, 21.90.

(S)-8-Amino-3-[2,3-dihydroxypropyl]-6-phenylimidazo[4',5':5,6]pyrido[2,3-*d*]pyrimidine (3**).** A solution of **8** (0.55 g, 1.5 mmol) in 80% AcOH (15 mL) was stirred at 60 °C for 22 h. The mixture was concentrated. The residue was purified by column chromatography (SiO₂, 1% MeOH in CHCl₃) to give **3** (0.31 g, 0.91 mmol) in 67% yield: ¹H NMR (400 MHz, DMSO-*d*₆) δ 3.34-3.47 (m, 2H), 3.95-3.98 (m, 1H), 4.16-4.18 (dd, *J* = 13.7 and 8.2, 1H), 4.51-4.54 (dd, *J* = 10.3 and 3.4, 1H), 4.94-4.96 (t, *J* = 5.9, 1H), 5.18 (d, *J* = 5.5, 1H), 7.49-7.51 (m, 3H), 8.04 (s, 2H), 8.50-8.52 (dd, *J* = 7.6 and 2.1, 2H), 8.58 (s, 1H),

9.04 (s, 1H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 47.9, 64.3, 69.9, 105.3, 123.5, 128.6, 128.7, 130.8, 134.4, 139.0, 151.0, 152.5, 156.5, 162.2, 164.6. Anal. Calcd for $\text{C}_{17}\text{H}_{16}\text{N}_6\text{O}_2 \cdot 1/5\text{H}_2\text{O}$: C, 59.99; H, 4.86; N, 24.12. Found: C, 60.25; H, 4.97; N, 24.21.

(S)-8-Amino-3-(2,3-dihydroxypropyl)-6-(4-dimethylaminophenyl)imidazo[4',5':5,6]pyrido[2,3-*d*]pyrimidine (4). Compound **7** (0.25 g, 0.92 mmol) and 4-dimethylaminobenzonitrile (2.68 g, 18.3 mmol) were dissolved in 7 M methanolic NH_3 (10 mL) in a stainless steel portable reactor at 0 °C. The portable reactor was sealed and the resulting solution was stirred at 140 °C for 2 days. After cooling the mixture, the tube was opened and the excess NH_3 was allowed to escape slowly. The mixture was concentrated. The residue was purified by column chromatography (SiO_2 , 5% MeOH in CHCl_3) to give **9** with a small amount of impurity. Subsequently, compound **9** (0.20 g, 0.48 mmol) was dissolved in 80% AcOH (10 mL) and the resulting mixture was stirred at 60 °C for 22 h. The mixture was concentrated. The residue was purified by column chromatography (SiO_2 , 17% MeOH in CHCl_3) to give **4** (0.11 g, 0.29 mmol) in 64% yield: ^1H NMR (400 MHz, DMSO- d_6) δ 3.00 (s, 6H), 3.37-3.49 (m, 2H), 3.91-3.98 (m, 1H), 4.13 (dd, $J = 13.8$ and 8.7 , 1H), 4.49 (dd, $J = 13.7$ and 3.2 , 1H), 4.92 (t, $J = 5.7$, 1H), 5.15 (d, $J = 5.5$, 1H), 6.78 (d, $J = 9.2$, 2H), 7.83 (s, 2H), 8.34 (d, $J = 9.2$, 2H), 8.51 (s, 1H), 8.95 (s, 1H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 46.3, 63.6, 69.3, 104.2, 111.1, 122.8, 125.6, 129.3, 133.1, 149.6, 151.7, 156.1, 162.0, 163.5. Anal. Calcd for $\text{C}_{19}\text{H}_{21}\text{N}_7\text{O}_2 \cdot 2/5\text{H}_2\text{O} \cdot 1/2\text{CH}_3\text{CO}_2\text{H}$: C, 57.65; H, 5.76; N, 23.53. Found: C, 57.32; H, 5.67; N, 23.85.

(S)-8-Amino-3-(2,3-dihydroxypropyl)-6-(4-methoxyphenyl)imidazo[4',5':5,6]pyrido[2,3-*d*]pyrimidine (5). Compound **7** (1.00 g, 3.66 mmol) and anisonitrile (9.74 g, 73.2 mmol) were dissolved in 7 M methanolic NH_3 (40 mL) in a stainless steel portable reactor at 0 °C. The portable reactor was sealed and the resulting solution was stirred at 140 °C for 2 days. After cooling the mixture, the tube was opened and the excess NH_3 was allowed to escape slowly. The mixture was concentrated. The residue was purified by column chromatography (SiO_2 , 5% MeOH in CHCl_3) to give **10** with a small amount of impurity. Subsequently, compound **10** was dissolved in 80% AcOH (40 mL) and the resulting mixture was stirred at 60 °C for 22 h. The mixture was concentrated. The residue was purified by column chromatography (SiO_2 , 10% MeOH in CHCl_3) to give **5** (0.86 g, 2.35 mmol) in 64% yield: ^1H NMR (400 MHz, DMSO- d_6) δ 3.38-3.52 (m, 2H), 3.83 (s, 3H), 3.92-4.01 (m, 1H), 4.12-4.18 (dd, $J = 13.7$ and 8.7 , 1H), 4.49-4.56 (dd, $J = 14.2$ and 3.6 , 1H), 4.90-4.92 (t, $J = 5.5$, 1H), 5.14-5.19 (d, $J = 5.5$, 1H), 7.03-7.06 (d, $J = 8.7$, 2H), 7.95 (s, 2H), 8.44-8.46 (dd, $J = 4.0$ and 3.3 , 2H), 8.55 (s, 1H), 9.00 (s, 1H); ^{13}C -NMR (100 MHz, DMSO- d_6) δ 47.1, 55.8, 64.3, 69.9, 105.0, 114.1, 123.5, 130.3, 131.5, 134.1, 150.8, 152.4, 156.6, 161.7, 162.0, 164.5; HRMS (DART) calcd for $\text{C}_{18}\text{H}_{18}\text{N}_6\text{O}_3$ ($\text{M}+\text{H}^+$): 367.1517, found; 367.1485. Anal. Calcd for $\text{C}_{18}\text{H}_{18}\text{N}_6\text{O}_3 \cdot 1/3\text{H}_2\text{O}$: C, 58.04; H, 5.05; N, 22.56. Found: C, 58.01; H, 5.08; N, 22.26.

(S)-8-Amino-3-(2,3-dihydroxypropyl)-6-furanylimidazo[4',5':5,6]pyrido[2,3-d]pyrimidine (6).

Compound **7** (0.25 g, 0.92 mmol) and 2-furonitrile (1.70 g, 18.3 mmol) were dissolved in 7 M methanolic NH₃ (40 mL) in a stainless steel portable reactor at 0 °C. The portable reactor was sealed and the resulting solution was stirred at 140 °C for 24 h. After cooling the mixture, the tube was opened and the excess NH₃ was allowed to escape slowly. The mixture was concentrated. The residue was purified by column chromatography (SiO₂, 5% MeOH in CHCl₃) to give **11** with a small amount of impurity. Subsequently, compound **11** was dissolved in 80% AcOH (40 mL) and the resulting mixture was stirred at 60 °C for 21 h. The mixture was concentrated. The residue was purified by column chromatography (SiO₂, 10% MeOH in CHCl₃) to give **6** (0.20 g, 0.63 mmol) in 70% yield: ¹H NMR (600 MHz, DMSO-*d*₆) δ 3.31-3.49 (m, 2H), 3.91-3.95 (m, 1H), 4.14 (dd, *J* = 14.4 and 8.2, 1H), 4.49 (dd, *J* = 11.0 and 3.4, 1H), 4.94 (t, *J* = 5.0, 1H), 5.18 (d, *J* = 4.8, 1H), 6.67 (dd, *J* = 3.5 and 1.4, 1H), 7.26 (d, *J* = 2.3), 7.87 (s, 1H), 8.08 (s, 2H), 8.56 (s, 1H), 9.00 (s, 1H); ¹³C NMR (151 MHz, DMSO-*d*₆) δ 47.0, 64.2, 69.8, 105.2, 112.7, 113.2, 123.4, 134.2, 145.4, 150.8, 152.3, 153.4, 155.8, 156.1, 164.5. Anal. Calcd for C₁₅H₁₄N₆O₃·1/3 H₂O: C, 54.22; H, 4.45; N, 25.29. Found: C, 54.44; H, 4.53; N, 25.00.

(S)-8-[(Di-*n*-butylamino)methyleneamino]-3-(2,3-dihydroxypropyl)-6-phenylimidazo[4',5':5,6]pyrido[2,3-d]pyrimidine (12).

A solution of **3** (0.10 g, 0.30 mmol) and *N,N*-di-*n*-butylformamide dimethyl acetal (0.30 g, 1.50 mmol) in DMF (2 mL) was stirred at 60 °C. After 24 h, the mixture was concentrated. The residue was purified by column chromatography (SiO₂, 5% MeOH in CHCl₃) to give **12** (0.12 g, 0.24 mmol) in 81% yield: ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.96-1.02 (m, 6H), 1.32-1.49 (m, 4H), 1.64-1.77 (m, 4H), 3.44-3.52 (m, 2H), 3.58-3.62 (t, *J* = 7.3, 2H), 3.74-3.78 (t, *J* = 7.8, 2H), 3.97-4.02 (m, 1H), 4.17-4.30, 4.54-4.58 (m, 2H), 4.90-4.93 (t, *J* = 6.0, 1H), 5.15-5.16 (d, *J* = 5.5, 1H), 7.53-7.55 (dd, *J* = 5.5 and 1.8, 3H), 8.62 (s, 1H), 8.63-8.64 (d, *J* = 4.2, 2H), 9.01 (s, 1H), 9.21 (s, 1H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 14.1, 14.3, 19.7, 20.3, 29.4, 31.0, 45.7, 47.0, 51.9, 64.3, 69.9, 111.8, 124.7, 128.9, 131.0, 135.0, 139.1, 151.3, 152.9, 157.0, 157.8, 161.4, 168.2; HRMS (DART) calcd for C₂₆H₃₃N₇O₂ (M+H⁺): 476.27740, found; 476.27936.

(S)-8-[(Di-*n*-butylamino)methyleneamino]-3-[3-(4,4'-dimethoxytrityloxy)-2-hydroxypropyl]-6-phenylimidazo[4',5':5,6]pyrido[2,3-d]pyrimidine (13).

A solution of **12** (0.40 g, 0.84 mmol) and DMTrCl (0.43 g, 1.30 mmol) in pyridine (6 mL) was stirred at room temperature. After 2 h, the mixture was partitioned between EtOAc and H₂O. The organic layer was washed with aqueous NaHCO₃ (saturated) and brine, dried (Na₂SO₄), and concentrated. The residue was purified by column chromatography (SiO₂, 33% EtOAc in hexane) to give **13** (0.47 g, 0.60 mmol) in 71% yield: ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.97-1.00 (m, 6H), 1.33-1.50 (m, 4H), 1.64-1.80 (m, 4H), 2.95-3.08 (m, 2H), 3.60-3.64, 3.76-3.79 (t, *J* = 7.3, 4H), 3.68 (s, 6H), 4.20-4.24 (dd, *J* = 14.2 and 7.3, 1H), 4.34-4.39, 4.51-4.55 (dd, *J* = 14.2 and 4.1, 2H), 5.42-5.44 (d, *J* = 6.0, 1H), 6.81-7.42 (m, 13H), 7.52-7.53 (m, 3H), 8.58 (s, 1H), 8.62-8.65 (q, *J* = 6.6

Hz, 2H), 8.98 (s, 1H), 9.21 (s, 1H); ^{13}C NMR (151 MHz, DMSO- d_6) δ 14.1, 14.3, 19.7, 20.3, 29.3, 31.0, 45.7, 47.3, 51.9, 55.5, 66.2, 68.3, 79.7, 86.0, 112.0, 113.6, 124.8, 127.1, 128.3, 128.9, 128.9, 130.3, 130.3, 131.0, 135.0, 136.1, 136.1, 139.1, 145.4, 151.2, 153.0, 157.2, 157.8, 158.5, 161.4, 168.4. Anal. Calcd for $\text{C}_{47}\text{H}_{51}\text{N}_7\text{O}_4 \cdot 3/2\text{H}_2\text{O}$: C, 70.13; H, 6.76; N, 12.18. Found: C, 69.95; H, 6.36; N, 11.85.

(S)-8-[(Di-*n*-butylamino)methyleneamino]-3-[3-(4,4'-dimethoxytrityloxy)-2-[(2-cyanoethoxy)(*N,N*-diisopropylamino)phosphanyl]oxy]propyl]-6-phenylimidazo[4',5':5,6]pyrido[2,3-*d*]pyrimidine (14).

A solution of **13** (0.37 g, 0.48 mmol), *N,N*-diisopropylethylamine (0.41 mL, 0.95 mmol), and chloro(2-cyanoethoxy)(*N,N*-diisopropylamino)phosphine (0.21 mL, 1.48 mmol) in THF (3 mL) was stirred at room temperature. After 30 min, the mixture was partitioned between CHCl_3 and H_2O . The organic layer was washed with aqueous NaHCO_3 (saturated) and brine, dried (Na_2SO_4), and concentrated. The residue was purified by column chromatography (SiO_2 , 50% EtOAc in hexane) to give **14** (0.43 g, 0.43 mmol) in 91% yield: ^{31}P -NMR (162 MHz, DMSO- d_6) δ 149.0, 149.9.

Oligonucleotide Synthesis. The synthesis was carried out with a DNA/RNA synthesizer by the phosphoramidite method. In the case of the coupling of the amidite **14**, a 0.15 M solution of the amidite **14** in MeCN was used. Deprotection of the bases and phosphates was performed in concentrated NH_4OH at 55 °C for 16 h. The oligonucleotides were purified by 20% PAGE containing 7 M urea to give the highly purified oligonucleotides, **BA** (26), **BG** (38), **BC** (43), **BT** (41), **AB** (36), **GB** (30), **CB** (34), and **TB** (33). The yields are indicated in parentheses as OD units at 260 nm starting from 1.0 μmol scale.

MALDI-TOF/MS Analyses of Oligonucleotides. Spectra were obtained with a SHIMADZU AXIMA-CFR plus time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3-ns pulse). **BA** $m/z = 5919.2$ ($[\text{M} - \text{H}]^-$, calcd 5919.9; $\text{C}_{194}\text{H}_{237}\text{N}_{75}\text{O}_{109}\text{P}_{18}$); **BG** $m/z = 5931.0$ ($[\text{M} - \text{H}]^-$, calcd 5935.9; $\text{C}_{194}\text{H}_{237}\text{N}_{75}\text{O}_{110}\text{P}_{18}$); **BC** $m/z = 5896.3$ ($[\text{M} - \text{H}]^-$, calcd 5895.9; $\text{C}_{193}\text{H}_{237}\text{N}_{73}\text{O}_{110}\text{P}_{18}$); **BT** $m/z = 5906.6$ ($[\text{M} - \text{H}]^-$, calcd 5910.9; $\text{C}_{194}\text{H}_{238}\text{N}_{72}\text{O}_{111}\text{P}_{18}$); **AB** $m/z = 5914.9$ ($[\text{M} - \text{H}]^-$, calcd 5919.9; $\text{C}_{194}\text{H}_{237}\text{N}_{75}\text{O}_{109}\text{P}_{18}$); **GB** $m/z = 5932.4$ ($[\text{M} - \text{H}]^-$, calcd 5935.9; $\text{C}_{194}\text{H}_{237}\text{N}_{75}\text{O}_{110}\text{P}_{18}$); **CB** $m/z = 5892.1$ ($[\text{M} - \text{H}]^-$, calcd 5895.9; $\text{C}_{193}\text{H}_{237}\text{N}_{73}\text{O}_{110}\text{P}_{18}$); **TB** $m/z = 5907.6$ ($[\text{M} - \text{H}]^-$, calcd 5910.9; $\text{C}_{194}\text{H}_{238}\text{N}_{72}\text{O}_{111}\text{P}_{18}$).

Fluorescence Experiments. Steady-state fluorescence emission spectra (370–670 nm) were obtained on a SHIMADZU RF-5300PC spectrofluorophotometer in quartz cuvettes with a path length of 1.0 cm and a 30 μM **B** concentration in an appropriate solvent or a 3.0 μM duplex concentration in a buffer comprising 10 mM sodium phosphate (pH 7.0) and 0.1 M NaCl at 20 °C. Spectra were recorded with use of excitation slit of 1.5 nm and emission slit of 1.5 nm for **B** or excitation slit of 3.0 nm and emission slit of 3.0 nm for the duplexes. The fluorescence quantum yield (Φ_{em}) was determined by use of quinine as a reference with the known Φ_{em} value of 0.58 (22 °C) in 0.1 M H_2SO_4 . The quantum yield was calculated

according to the following equation: $\Phi_{em(S)}/\Phi_{em(R)} = (I_{(S)}/I_{(R)}) \times (A_{(S)}/A_{(R)}) \times (n_{(S)}^2/n_{(R)}^2)$. Here, $\Phi_{em(S)}$ and $\Phi_{em(R)}$ are the fluorescence quantum yields of the sample and the reference, respectively, $I_{(S)}$ and $I_{(R)}$ are the integrated fluorescence intensities of the sample and the reference, respectively, $A_{(S)}$ and $A_{(R)}$ are the respective optical density of the sample and the reference solutions at the wavelength of excitation, and $n_{(S)}^2$ and $n_{(R)}^2$ are the values of the refractive index for the respective solvents.

ACKNOWLEDGEMENTS

This research was partially supported by the Ministry of Education, Culture, Sports, Science, and Technology of Japan (Grant-in-Aid for Exploratory Research, 24659045) and by a C19 Kiyomi Yoshizaki research grant.

REFERENCES

1. S. Kim and A. Misra, *Annu. Rev. Biomed. Eng.*, 2007, **9**, 289; R. Nielsen, J. S. Paul, A. Albrechtsen, and Y. S. Song, *Nature Rev. Genet.*, 2011, **12**, 443; N. R. Wray, J. Yang, B. J. Hayes, A. L. Price, M. E. Goddard, and P. M. Visscher, *Nature Rev. Genet.*, 2013, **14**, 507.
2. A. Okamoto, K. Tanaka, and I. Saito, *J. Am. Chem. Soc.*, 2003, **125**, 4972; O. Köhler and O. Seitz, *Chem. Commun.*, 2003, 2938.
3. K. Furukawa, M. Hattori, T. Ohki, Y. Kitamura, Y. Kitade, and Y. Ueno, *Bioorg. Med. Chem.*, 2012, **20**, 16; M. Hattori, T. Ohki, E. Yanase, and Y. Ueno, *Bioorg. Med. Chem. Lett.*, 2012, **22**, 253.
4. Related works. P. A. Harris and W. Pendergast, *J. Heterocycl. Chem.*, 1996, **33**, 319; A. T. Krueger and E. T. Kool, *J. Am. Chem. Soc.*, 2008, **130**, 3989.
5. R. Marumoto, Y. Yoshioka, O. Miyashita, S. Shima, K. Imai, K. Kawazoe, and M. Honjo, *Chem. Pharm. Bull.*, 1975, **23**, 759; Y. Sato, T. Maruyama, and M. Honjo, *Chem. Pharm. Bull.*, 1989, **37**, 1604.
6. A. E. Rettie, L. C. Wienkers, F. J. Gonzalez, W. F. Trager, and K. R. Korzekwa, *Pharmacogenetics*, 1994, **4**, 39; T. H. Sullivan-Klose, B. I. Ghanayem, D. A. Bell, Z.-Y. Zhang, L. S. Kaminsky, G. M. Shenfield, J. O. Miners, D. J. Birkett, and J. A. Goldstein, *Pharmacogenetics*, 1996, **6**, 341.